Acetylsalicylic acid was included on the first EML in 1977 as an analgesic/antipyretic/non-steroidal anti-inflammatory medicine. It was included in the complementary list of the first EMLc in 2007 specifically for use in rheumatic fever, juvenile arthritis, and Kawasaki disease. The EMLc Subcommittee agreed that the management of pain in children is an essential clinical need but that aspirin is not recommended for use in children under 16 years in many settings, and had only a limited role, if any, in the management of inflammatory conditions in children. This listing was deleted in 2013, and a new section (Section 30: Medicines for diseases of joints) was created which included acetylsalicylic acid for juvenile joint diseases.